Vaccine that targets several amyloid (Aβ) and tau pieces for Alzheimer's
Mosaic Display of Multivalent Tau and A-Beta peptides on Immunogenic SNAP Liposomes
This project is making a vaccine that trains the immune system to target both amyloid and tau proteins to help people at risk for or living with Alzheimer's disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pop Biotechnologies, INC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11256011 on NIH RePORTER |
What this research studies
Researchers are creating a 'mosaic' vaccine that displays multiple pieces of the Aβ and tau proteins on tiny lipid particles called SNAP liposomes to trigger a broader immune response. They will scale up manufacturing, develop quality and analytical tests, and run lab and animal studies to check immune responses, safety, and effects on Alzheimer-like brain changes. The work uses established Alzheimer's animal models and preclinical safety testing as steps toward an Investigational New Drug (IND) application. If those steps go well, the vaccine could move into early human safety trials.
Who could benefit from this research
Good fit: People at risk for Alzheimer's disease or in the early stages of Alzheimer's would be the most likely candidates for future vaccine trials.
Not a fit: People with advanced Alzheimer's, significant immune disorders, or known allergies to vaccine components may not be suitable or receive benefit.
Why it matters
Potential benefit: If successful, this vaccine could lower both amyloid and tau pathology and potentially slow or prevent cognitive decline in people with or at risk for early Alzheimer's disease.
How similar studies have performed: Some monoclonal antibodies that clear amyloid have modestly slowed decline in early Alzheimer's, but combined vaccines targeting both amyloid and tau are largely novel and unproven in humans.
Where this research is happening
Buffalo, United States
- Pop Biotechnologies, INC — Buffalo, United States (Active)
Researchers
- Principal investigator: Huang, Wei-Chiao — Pop Biotechnologies, INC
- Study coordinator: Huang, Wei-Chiao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.